好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Epilepsy Quality Measures To Improve Performance (EQUIP): A Practical 10-Point Score For Assessing Epilepsy Quality Measures In Routine Clinical Practice.
Epilepsy/Clinical Neurophysiology (EEG)
P11 - Poster Session 11 (11:45 AM-12:45 PM)
11-005
To evaluate the use and documentation of the EQUIP measures in routine clinical practice
Epilepsy quality measures (EQM) established by the 好色先生 (AAN-EQM) and National Association of Epilepsy Centers (NAEC) outpatient measures aim to improve care quality, yet their adoption in routine clinical practice remains limited. Several measures have been retired due to challenges in obtaining data from unstructured clinical notes. We reviewed AAN, NAEC, and Quality Indicators in Epilepsy Treatment (QUIET) guidelines (including retired measures) and selected specific measures to create the EQUIP measures—a shorter, structured, measurable, and scalable 10-point score.
We prospectively reviewed 232 outpatient epilepsy encounters at Yale Epilepsy Center (November 2024 to October 2025). EQUIP score includes 10 primary quality measures across four domains: seizure metrics (frequency, type, etiology, date of last seizure, severe seizures, status epilepticus and seizure clusters), treatment (medication adherence), comorbidity (behavioral health screening), and counseling/education (driving/safety, lifestyle/trigger counseling), plus reproductive health counseling for childbearing age women. Each measure was scored using a binary system (1 point per completed measure), calculated as (completed measures/total applicable measures) × 100%.

Among 232 participants (mean age 46.35 years, 48.7% [n=113] female, 70% [n=162] Caucasian, 40% [n=91] unemployed), the cohort was stratified by applicable measures: males and non-childbearing women (78.6%, n=176) and childbearing potential females (21.4%, n=48). Mean overall EQUIP scores were 7.27 (SD=1.45) and 7.29 (SD=2.4) respectively. Seizure-specific assessments (mean: 4.48 and 4.40, SD: 0.87 and 0.96) and treatment measures (mean: 1.54, and 1.46, SD: 0.63 and 0.74) were highly documented, while comorbidity measures (mean: 0.39 and 0.33, SD: 0.49 and 0.48) and education/counseling measures (mean: 0.89 and 1.1, SD: 0.86 and 1.12) were less documented.
We demonstrated the use of the EQUIP quality measurement score in routine clinical practice. Feasibility data are being collected through semi-structured qualitative interviews to further inform implementation.
Authors/Disclosures
Sohail M. Dewain, MD
PRESENTER 		Dr. Dewain has nothing to disclose.
Saifeldin Hossameldin, MD Dr. Hossameldin has nothing to disclose.
Poojith Nuthalapati, MD Mr. Nuthalapati has nothing to disclose.
Margaret Gopaul, PhD (Yale School of Medicine) Dr. Gopaul has nothing to disclose.
Abigail Herbst Ms. Herbst has received personal compensation for serving as an employee of Thermo Fisher Scientific.
Bridget A. Gaglio, PhD Ms. Gaglio has received personal compensation for serving as an employee of Thermo Fisher Scientific.
Priyanka Deep Miss Deep has nothing to disclose.
Kelly F. Fischbein, RN Ms. Fischbein has received personal compensation for serving as an employee of UCB Inc.. Ms. Fischbein has stock in UCB Inc..
Hamada H. Altalib, DO (VA Connecticut Healthcare System) The institution of Dr. Altalib has received research support from UCB. The institution of Dr. Altalib has received research support from DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS.